Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies

Current Opinion in Oncology

Volumn 10, Issue 6, 1998, Pages 542-547

  Schultze, Joachim L ^a   Gribben, John G ^a   Nadler, Lee M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD40 ANTIGEN; PEPTIDE; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL MODEL; B CELL LEUKEMIA; B CELL LYMPHOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0031786844     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199811000-00011     Document Type: Review

References (31)

1. Cheever MA, Chen W: Therapy with cultured T cells: principles revisited. Immunol Rev 1997, 157:177-194. Comprehensive review about the basic principles of antigen-and tumor-specific adoptive T-cell transfer. This review summarizes elegantly the work of two decades. The role of appropriate in vitro culture conditions in addition to the role of restimulation of adoptively transferred T cells with IL-2 and antigen is covered. Moreover, the influence of chemotherapy in such strategies is discussed. In addition, recent attempts to characterize antigens recognized by tumor-specific T cells and their use for immunotherapy are included.
2. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241. First demonstration of the safety, feasibility, and efficacy of adoptively transferred antigen-specific T cells in the human. This work has set the gold standard for further attempts to adoptively transfer antigen-specific T cells.
3. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
4. Riddell SR, Greenberg PD: Principles for adoptive T cell therapy of human viral diseases. Ann Rev Immunol 1995, 13:545-586. Extensive review about the effector mechanisms of adoptively transferred T cells in human viral disease and the potential obstacles to this therapeutic strategy.
5. Yee C, Riddell SR, Greenberg PD: Prospects for adoptive T cell therapy. Curr Opin Immunol 1997, 9:702-708.
6. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, et al.: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555.
7. O'Reilly RJ, Small TN, Papdopoulos E, Lucas K, Lacerda J, Koulova L: Biology and adoptive cell therapy of Epstein-Barr virus-associated lympho-proliferative disorders in recipients of marrow allografts. Immunol Rev 1997, 157:195-216.
8. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al.: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994, 86:1159-1166.
9. Cheever MA, Thompson DB, Klarnet JP, Greenberg PD: Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med 1986, 163:1100-1112.
10. Chen W, Reese VA, Cheever MA: Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2. J Immunol 1990, 144:3659-3666.
11. Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever MA: T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 1991, 146:4414-4420.
12. Riddell SR, Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990, 128:189-201.
13. Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM: Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997, 89:3806-3816. First demonstration that human malignant B cells altered by a physiologic signal, namely CD40 ligation, can be used to stimulate the patient's T cells and that the generated T-cell lines can also recognize the primary tumor cells. Clear evidence is presented that lymphoma cells are susceptible to T-cell-mediated lysis. In addition, this paper demonstrates the importance of cytokines during an ex vivo expansion for the outcome of T-cell expansion and effector function.
14. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, et al.: Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A 1995, 92:8200-8204. Demonstration that malignant B cells are poor APCs despite their expression of major histocompatibility class I and II molecules on the cell surface. This is the first report showing that malignant B cells can be turned into highly efficient APCs by CD40 ligation and that these cells can be used to stimulate allogeneic T cells to recognize unaltered malignant B cells.
15. Ranheim EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993, 177:925-935.
16. Shamash J, Davies DC, Salam A, Rohatiner AZ, Young BD, Lister TA: Induction of CD80 expression in low-grade B cell lymphoma: a potential immunotherapeutic target. Leukemia 1995, 9:1349-1352.
17. Vyth-Dreese FA, Dellemijn TA, Van Oostveen JW, Feltkamp CA, Hekman A: Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell non-Hodgkin's lymphoma cells. Blood 1995, 85:2802-2812.
18. Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, et al.: Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996, 88:41-48.
19. Dorfman DM, Schultze JL, Shahsafaei A, Michalak S, Gribben JG, Freeman GJ, et al.: In vivo expression of B7-1 and B7-2 on follicular lymphoma is not sufficient to induce significant T cell proliferation but is sufficient to prevent T cell anergy in vitro. Blood 1997, 90:4297-4306. This paper clearly shows that all human germinal center-derived lymphomas but not B chronic lymphocytic leukemia express the costimulatory molecules B7-1 and B7-2 on their surface. However, the expression is insufficient to induce a profound antitumor T-cell response in B-cell malignancies.
20. Staveley OCK, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, et al.: Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998, 95:1178-1183. Elegant paper suggesting that T-cell unresponsiveness in a murine transgenic lymphoma model is induced early during lymphoma progression.
21. Girolomoni G, Ricciardicastagnoli P: Dendritic cells hold promise for immunotherapy. Immun Today 1997, 18:102-104.
22. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A: Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996, 66:470-476. Targeting single tumor antigens can lead to the outgrowth of antigen-loss variants. This obstacle of immunotherapy targeting single antigens is shown here for patients with melanoma after peptide vaccination. However, this phenomenon is likely to be true for adoptive T-cell transfer of single T-cell clones specific for one particular antigen.
23. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, et al.: CD40 activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997, 100:2757-2765. Normal B cells activated via CD40 as an alternative approach to dendritic cells, EBV-transformed B cells of the tumor cells themselves to ex vivo expand autologous antigen-specific T cells. The methodology described is easy, inexpensive, and provides massive numbers of highly efficient APCs for a very long period of time. CD40-activated B cells can be rapidly generated from very small amounts of peripheral blood.
24. Khanna R, Cooper L, Kienzle N, Moss DJ, Burrows SR, Khanna KK: Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol 1997, 159:5782-5785.
25. Faasen AE, Dalke DP, Berton MT, Warren WD, Pierce SK: CD40-CD40 ligand interactions stimulate B cell antigen processing. Eur J Immunol 1996, 25:3249-3255.
26. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, et al.: Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 1997, 90:549-561. Demonstration of autologous leukemia-specific T cells, with a similar methodology as described for follicular lymphoma (see also Schultze et al. [Blood 1997, 89:3806-3816]).
27. Janeway CA Jr, Sakato N, Eisen HN: Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci U S A 1975, 72:2357-2360.
28. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992, 327:1209-1215.
29. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52-58.
30. Parkman R, Weinberg KI: Immunological reconstitution following bone marrow transplantation. Immunol Rev 1997, 157:73-78.
31. Toes RE, van der Voort EI, Schoenberger SP, Drijfhout CJ: Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998, 160:4449-4456. This article makes an important observation, emphasizing that an appropriate delivery of a particular antigen is absolutely crucial for the success of many different immunotherapeutic strategies. Although these findings are especially important for vaccination strategies, they also have an impact on the generation and subsequent restimulation of antigen-specific T cells in vitro and in vivo after adoptive transfer of these T cells.